Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HK2 | P52789 | 5/20 | 0.44 |
| ▸ | HK1 | P19367 | 4/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28919637 | 1.00 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10344862 | 1.00 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10325486 | 1.00 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL18819836 | 0.81 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL12580215 | 0.81 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL23133630 | 0.81 | KDM4E (0.47) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL16328380 | 0.81 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL18542696 | 0.81 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10099542 | 0.81 | KDM4E (0.47) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL16580127 | 0.81 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-06-15 | — | — | US | disclosed |
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4121060-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | Board of Regents, The University of Texas System (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115515601-A | Methods of treating viral infections with hexose-type monosaccharides and analogs thereof | 得克萨斯大学体系董事会 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021188586-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-23 | — | — | WO | disclosed |
| US-10478446-B2 | Compounds for use in polycystic kidney disease | FONDAZIONE CENTRO SAN RAFFAELE OFFICE OF BIOTECHNOLOGY TRANSFER (IT) | 2019-11-19 | — | — | US | disclosed |
| US-20150297620-A1 | COMPOUNDS FOR USE IN POLYCYSTIC KIDNEY DISEASE | FONDAZIONE TELETHON ETS (IT) | 2015-10-22 | — | — | US | disclosed |
| US-20150297620-A1 | COMPOUNDS FOR USE IN POLYCYSTIC KIDNEY DISEASE | FONDAZIONE TELETHON ETS (IT) | 2015-10-22 | — | — | US | disclosed |
| EP-2663314-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | The University of Texas M.D. Anderson Cancer (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012097052-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, GLS, GLS2 | KDM4E 3871/4885LMNA 3822/4885CYP2D6 3538/4885 |
| US-20230130134-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF | G6PD, FBP1, ALDOA | KDM4E 1648/4885LMNA 3251/4885CYP2D6 519/4885 |
| US-20150297620-A1 | COMPOUNDS FOR USE IN POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, GLS | KDM4E 3341/4885LMNA 3658/4885CYP2D6 4790/4885 |
| US-20120276108-A1 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | IGF1R, IRS1, IGFBP1 | KDM4E 3381/4885LMNA 3624/4885CYP2D6 4121/4885 |
| US-10478446-B2 | Compounds for use in polycystic kidney disease | PKD1, PKD2, GLS | KDM4E 3341/4885LMNA 3658/4885CYP2D6 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.